AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility

AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.

Revolutionizing Drug Discovery: The Evolution from Target-Selective Design to AI-Powered Polypharmacology

Drug Discovery, Target-Selective Design, AI-Enabled Polypharmacology, Machine Learning, Systems Biology, Multi-Target Drugs, Personalized Medicine.

Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results

Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.